SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (BSD) (NASDAQ:BSDM) announced today that The Lancet Oncology, the premier worldwide journal for original oncology research, has issued a press release regarding the publication of the results of a Phase III clinical study of hyperthermia using the BSD-2000 Hyperthermia System, combined with chemotherapy for the treatment of high-risk soft-tissue sarcoma cancer (STS) patients, “Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study”. (The Lancet Oncology, Early Online Publication, 29 April 2010, doi:10.1016/S1470-2045(10)70071-1 .) The complete text of The Lancet Oncology press release has been included below.
